[Aliskiren (Rasilez), direct renin inhibitor].
Aliskiren (Rasilez) is the first oral renin inhibitor. Its present indication is essential hypertension, as monotherapy or in combination with other antihypertensive agents (diuretic, calcium antagonist, ...). It may also be associated with an angiotensin converting enzyme inhibitor (or an AT1 angiotensin receptor antagonist) in order to benefit of a dual blockade of the renin-angiotensin-aldosterone system. The usual daily dose is 150 mg, to be increased up to 300 mg if necessary. New clinical trials are ongoing to validate this novel therapeutic approach in other indications such as congestive heart failure and diabetic nephropathy.
Scheen
A J
AJ
Université de Liège, Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU Sart Tilman, Liège, Belgique.
Piérard
L
L
Krzesinski
J M
JM
D000577:Amides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005650:Fumarates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000092502:Renin Inhibitors
D000577:Amides; D005650:Fumarates; D000092502:Renin Inhibitors; C446481:aliskiren